STX17 and nonpapillary renal cell carcinoma: To study whether STX17-DT is involved in clinical ccRCC progression, we analyzed the expression of STX17-DT in our SCU cohort, in which each ccRCC patient experienced relapse or metastasis and received axitinib treatment.